Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960816 | 0.92 | GABRA5 (0.40) | GABRA5GABRA2GABRB2ALDH1A1KDM4E | |
| SCHEMBL2688051 | 0.87 | GABRA5 (0.52) | GABRA5GABRA1 | |
| SCHEMBL2687970 | 0.87 | GABRA5 (0.40) | GABRA5GABRA2GABRB2ALDH1A1KDM4E | |
| SCHEMBL16086884 | 0.87 | GABRA5 (0.49) | GABRA5GABRA2GABRB2ALDH1A1KDM4E | |
| SCHEMBL2688068 | 0.83 | GABRA5 (0.53) | GABRA5NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL2688063 | 0.83 | GABRA5 (0.52) | GABRA5GABRA1 | |
| SCHEMBL2687254 | 0.81 | ITGA5 (0.42) | GABRA5ALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL6466999 | 0.80 | GABRA1 (0.51) | GABRA5GABRA1 | |
| SCHEMBL2687615 | 0.78 | GABRA5 (0.55) | GABRA5GABRA2GABRB2ALDH1A1GAA | |
| SCHEMBL1776149 | 0.78 | GABRA5 (0.63) | GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | claimed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | claimed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | GABRA5 1/4885GABRA2 11/4885GABRB2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.